Understand the source comparison
TB-4 Research Sleep Quality Considerations: Study Design Comparison
Healthy volunteers (no injury) CRP <1.0 mg/L, IL-6 <2.0 pg/mL Morning (8:00 AM) No measurable change in REM latency or N3 percentage Yes. Wearables insufficient TB-4's sleep effects are statistically undetectable in low-inflammation populations dosed outside t
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Healthy volunteers (no injury)
- CRP <1.0 mg/L, IL-6 <2.0 pg/mL
- Morning (8:00 AM)
- No measurable change in REM latency or N3 percentage
- Yes. Wearables insufficient
- TB-4's sleep effects are statistically undetectable in low-inflammation populations dosed outside the circadian nadir window
- Injury recovery (rotator cuff repair)
- CRP 3–8 mg/L, IL-6 3.5–6.0 pg/mL
- Evening (6:00 PM, 4h pre-sleep)
- REM latency reduced by 15–20 minutes, N3 percentage increased by 25–35%
- Yes. Architecture changes require EEG
- Inflammation resolution drives measurable sleep improvements when dosing timing aligns with circadian protein expression
- Chronic musculoskeletal pain models
- CRP 2–5 mg/L, persistent IL-1beta elevation
- Twice daily (morning + evening)
- Sleep efficiency improved from 78% to 86%, fewer awakenings in second sleep cycle half
- Yes. Micro-arousals require EEG detection
- Twice-daily dosing maintains continuous anti-inflammatory coverage across the full circadian cycle, improving sleep continuity independent of timing
- Cognitive function research (healthy aging)
- Normal inflammatory markers, mild age-related decline
- Morning (9:00 AM)
- No change in total sleep time, modest REM latency reduction (8 minutes)
- Optional. Effect size small
- TB-4's cognitive benefits in aging populations may operate through non-sleep pathways; sleep architecture changes are secondary